EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tralokinumab monotherapy improves atopic dermatitis severity in patients with moderate-to-severe atopic hand eczema

Benjamin D. Ehst, H. Chih-ho Hong, Leon Kircik, Francisco J. Navarro-Trivino, April W. Armstrong, Frida Emanuelsson, Anne Louise Svendsen, Ann-Marie Tindberg, Stephan Weidinger

SKIN The Journal of Cutaneous Medicine · 10.11.2026 · 10 (6) · s884

DOI: 10.25251/k6f47m19 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.11.2026. Verfasst von Benjamin D. Ehst und 8 weiteren Autor:innen. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Atopic dermatitis (AD) is a chronic inflammatory skin disease that commonly affects multiple body regions, with involvement of the head, neck, and hands often being particularly burdensome. ADHAND was the first phase 3 trial to evaluate targeted IL-13 inhibition in patients with AD and moderate-to-severe hand involvement. At Week 16, tralokinumab monotherapy significantly improved AD hand-specific signs and symptoms, and quality of life. Patients in ADHAND were required to have AD affecting at least one body area beyond the hands. Here, we assess the efficacy of tralokinumab monotherapy versus placebo on overall AD severity beyond the hands in the ADHAND study population.

Methods

ADHAND (NCT05958407) was a phase 3b, randomized, controlled, double-blind trial. Participants were randomized 2:1 to receive tralokinumab monotherapy 300 mg or placebo, every two weeks, for 16 weeks. Predefined exploratory outcomes included the proportion of patients achieving ≥75% or ≥90% reduction from baseline to Week 16 in Eczema Area and Severity Index (EASI-75/90). Predefined subgroup analyses were based on baseline disease severity: EASI≤7 (mild), EASI>7 (moderate-to-severe), and EASI≥16 (inclusion criterion used in the tralokinumab pivotal trials). Statistical analyses followed pre-specifications; data after rescue treatment, discontinuation due to adverse events, or discontinuation due to lack of efficacy were imputed as non-response, while other missing data were handled using multiple imputation.

Results

Baseline mean (±SD) EASI was similar in the tralokinumab monotherapy group (N=156; 9.18±9.10) and placebo group (N=78; 9.33±8.83). Of the 234 patients included in the analysis, 136 had baseline EASI≤7 (tralokinumab n=92; placebo n=44), 98 had EASI>7 (tralokinumab n=64; placebo n=34), and 36 had EASI≥16 (tralokinumab n=24; placebo n=12). At Week 16, a higher proportion of all patients receiving tralokinumab monotherapy achieved EASI-75 (47.6% vs 19.8%) and EASI-90 (27.9% vs 9.5%) versus placebo (both P

Zitieren

APA

Ehst, B. D., Hong, H. C., Kircik, L., Navarro-Trivino, F. J., Armstrong, A. W., Emanuelsson, F., Svendsen, A. L., Tindberg, A., & Weidinger, S. (2026). Tralokinumab monotherapy improves atopic dermatitis severity in patients with moderate-to-severe atopic hand eczema. SKIN The Journal of Cutaneous Medicine, 10(6), s884. https://doi.org/10.25251/k6f47m19

Vancouver

Ehst BD, Hong HC, Kircik L, Navarro-Trivino FJ, Armstrong AW, Emanuelsson F, et al. Tralokinumab monotherapy improves atopic dermatitis severity in patients with moderate-to-severe atopic hand eczema. SKIN The Journal of Cutaneous Medicine. 2026;10(6):s884. doi:10.25251/k6f47m19

BibTeX
@article{Ehst2026,
  author = {Ehst, Benjamin D. and Hong, H. Chih-ho and Kircik, Leon and Navarro-Trivino, Francisco J. and Armstrong, April W. and Emanuelsson, Frida and Svendsen, Anne Louise and Tindberg, Ann-Marie and Weidinger, Stephan},
  title = {Tralokinumab monotherapy improves atopic dermatitis severity in patients with moderate-to-severe atopic hand eczema},
  journal = {SKIN The Journal of Cutaneous Medicine},
  year = {2026},
  volume = {10},
  number = {6},
  pages = {s884},
  doi = {10.25251/k6f47m19}
}
Kostenlos starten →